Full Judgment Text
REPORTABLE
IN THE SUPREME COURT OF INDIA
CIVIL APPELLATE JURISDICTION
CIVIL APPEAL NO. 4480 OF 2005
COMMISSIONER OF CENTRAL EXCISE,
HYDERABAD
.....APPELLANT(S)
VERSUS
M/S SARVOTHAM CARE LIMITED .....RESPONDENT(S)
W I T H
CIVIL APPEAL NO. 5752 OF 2015
(arising out of SLP (C) No. 1531 of 2015)
J U D G M E N T
A.K. SIKRI, J.
JUDGMENT
Civil Appeal No. 4480 of 2005
Respondent herein is the manufacture of 'Ketoconazole
Shampoo' and 'Nizral Shampoo' which are sold in the bottles of
50 ml and 5 ml. Dispute is about the classification of the
aforesaid product for the purposes of payment of central excise
duty. The respondent had filed the declaration classifying the said
product under CSH 3003.10 of the Central Excise Tariff Act, 1985
on the ground that it is basically a medicine. However, as per the
Civil Appeal Nos. 4480 of 2005 & Anr. Page 1 of 28
Page 1
appellant/Revenue, the appropriate classification of this product is
under CSH 3305.99 as it perceives the product as 'preparation for
use on on hair'.
2) Chapter 30 under which CSH 3003.10 falls deals with
Pharmaceuticals products and the aforesaid entry thereof reads
as under:
“Patent or proprietary medicaments, other than
those medicaments which are exclusively
Ayurvedic, Unani, Siddha, Homoeopathic or
Bio-chemic.”
On the other hand, Chapter 33 deals with the products
which fall under the nomenclature 'Essential Oils and Resinoids;
Perfumery, Cosmetic or Toilet Preparation'. The entry CSH
3305.99 thereof is as under:
“Preparations for use on the hair
-Perfumed hair oils
-Other :
--Hair fixer
--Other”
JUDGMENT
3) It becomes clear from the reading of the aforesaid two entries that
the respondent claims that the product in question belongs to the
specie of Pharmaceutical products i.e. medicinal product and is
covered by the expression 'patent or proprietary medicaments'.
On the other hand, the case of the Revenue is that it is simply a
Civil Appeal Nos. 4480 of 2005 & Anr. Page 2 of 28
Page 2
shampoo which is to be used for cleaning hair and is nothing but
a 'toilet preparation'. If the product is to be treated as
Pharmaceutical product covered by Entry 3003.10, excise duty
prescribed is 16%. The excise duty of goods covered by Entry
3305.99 is 24%.
4) The Revenue issued show cause notice demanding differential
duty amounting to Rs.8,12,194. After the reply was given by the
respondent along with the material placed by it before the
Adjudicating Authority, the Adjudicating Authority passed the
Order-in-Original dated 18.11.1999 for the period December, 1998
to April, 1999 confirming the differential duty of Rs.8,12,194 under
Section 4A read with Section 11A of the Central Excise Act, 1944.
In appeal preferred by the respondent, the aforesaid demand was
upheld by the Commissioner (Appeals) vide order in original
JUDGMENT
dated 13.02.2002, resulting in the dismissal of the appeal of the
respondent. Next level appeal filed by the respondent before the
CESTAT, Bangalore, however, yielded results favourable to the
respondent, as this appeal is allowed by the Tribunal vide final
Orders dated 18.01.2005 with consequential reliefs, if any. It was
held that there is enormous evidence to show that the product in
question was used for treatment of several disorders/diseases
and it has also been sold by Chemists under the prescription
Civil Appeal Nos. 4480 of 2005 & Anr. Page 3 of 28
Page 3
issued by the Registered Medical Practitioners or the Hospitals.
Therefore, it is a medicinal product and not simply a shampoo for
use of hair. Naturally, the Revenue is not satisfied with the
aforesaid view of the Tribunal and, therefore, has preferred the
instant appeal in this Court.
5) In his endeavour to demonstrate that the product 'Nizral
Shampoo' was simply a toilet preparation to be used on the hair
and could not be classified as a product belonging to the family of
Pharmaceutical products, Mr. Panda, learned senior counsel
appearing for the Revenue, drew our attention to the orders
passed by the Commissioner (Appeals) wherein findings in
respect of this product are arrived at after discussing the
ingredients/properties of the said product. On that basis, it was
argued (as reasoned by the Commissioner (Appeals) as well) that
JUDGMENT
there was no dispute raised even by the assessee that the
product 'Nizral' was basically a shampoo preparation. Even if it
was coupled with therapeutic or prophylactic properties imparted
to it with the presence of an anti-fungal agent known as
'Ketoconazole', this would not change the basic character of the
product viz. shampoo, which is meant for the use of cleaning hair.
It was argued that such a classification was in conformity with
Chapter Note (6) to Chapter 33 which specified 'shampoos'
Civil Appeal Nos. 4480 of 2005 & Anr. Page 4 of 28
Page 4
whether or not containing soap or organic surface active agent.
He further submitted that as per the packings, labels, leaflet
literature, it was apparent that the product in question was held
out commercially as having subsidiary curative or prophylactic
value with main purpose and the main purpose of the produce
was cleaning of scalp and hair. Therefore, Chapter Note (2) of
Chapter 33 also got attracted as per which how the product is
explained and marketed by the manufacturer itself becomes the
determining factor. It was also submitted that HSC of Chapter 33
also includes not only shampoos containing soap and OSAC, but
'other shampoos' as well which would imply that those products
which are essentially shampoos would still be treated as
shampoos even if the subsidiary benefits of using such a
shampoo would be curative in nature. On that basis, submission
JUDGMENT
was that presence of 'Ketoconazole' which was hardly 2% W/V in
the said shampoo making it anti-fungal agent, would not change
the pre-dominant character of the product as shampoo and turn it
into a patent or proprietary medicament classifiable under
Chapter sub-heading 3003.10. The learned senior counsel, in
this behalf, drew our attention to the following justification given
by the Commissioner (Appeal) in his order reflecting that mere 2%
of presence of 'Ketoconazole' would not make any difference:
Civil Appeal Nos. 4480 of 2005 & Anr. Page 5 of 28
Page 5
“It is rather unassailable that active ingredient
'Ketoconazole' is considered to prophylactic in
nature for it to treat the cause of dandruff.
Admitting that the active ingredient
'Ketoconazole' is for prophylactic for dandruff, it
is clear that the product 'Nizral Shampoo' shall
stand excluded from the purview of Chapter 30,
in view of Chapter Note 1(d) to Chapter 30
which lays down that 'Preparation of Chapter 33
even if they have therapeutic or prophylactic
properties' are not covered. On careful reading
of the above Chapter Notes, which are statutory
in nature and binding, a clear finding emerges
that the impugned goods have a specific entry
under Chapter 33 in terms of Chapter (6) to
Chapter 33. The heading which provides the
most specific description, shall be preferred to
headings providing a more general description
as per Rule 3(a) of Rules for the interpretations
of the Schedule. Hence, by all the above
statutory accounts the impugned goods would
not permit classification under Chapter 30 of
Central Excise Tariff Act, 1985 as medicament,
but only as a 'preparation for use on hair”.
6) It was further argued by Mr. Panda that merely because the
respondent was manufacturing this product on loan/licence basis
JUDGMENT
from Johnson & Johnson Ltd., with the express permission/
licence of Drug Controller of India and Food & Drug
Administration, would be of no avail to the respondent. Likewise,
even if it was sold by the Chemist would be of no significance as
the claim of the respondent that it could be sold only on specific
prescription of the registered medical practitioner was clearly
wrong as the respondent was widely publishing the product
through advertisements clearly conveying to the users that the
Civil Appeal Nos. 4480 of 2005 & Anr. Page 6 of 28
Page 6
same was available with leading Chemists. Mr. Panda referred to
those portions of the order of the Commissioner (Appeals) where
the aforesaid arguments of the respondent were discussed and
discarded. He pleaded that what was to be seen was the
pre-dominant use of the product in question; that is to say
whether the product 'Nizral Shampoo' was primarily used as a
shampoo or as a medicinal product and argued that the dominant
purpose of the product was to use it as a shampoo with
ancillary/added advantage being prevention of scalp related
infection i.e. dandruff.
7) To buttress the aforesaid submissions, Mr. Panda took the aid of
certain judgments of this Court. First judgment on which he relied
is in the case of Collector of Central Excise, Shillong v. Wood
1
Crafts Products Ltd. , wherein this Court emphasized that the
JUDGMENT
criteria/classification laid down by Harmonised System Committee
(HSC), established under Article 6 of the International Convention
on Harmonised System, is to be acted upon while deciding the
cases of classification inasmuch as it was an expert body which
was assigned the main function of preparing explanatory notes,
classification opinions or other advice as guides to the
interpretation of the Harmonised System and to secure uniformity
1 (1995) 3 SCC 454
Civil Appeal Nos. 4480 of 2005 & Anr. Page 7 of 28
Page 7
in the interpretation and application of the Harmonised System. It
was so held by this Court in the said judgment in the following
manner:
“11. The Statement of Objects and Reasons of
the Central Excise Tariff Bill, 1985 which led to
the enactment of the Central Excise Tariff Act,
1985 is indicative of the pattern of the structure of
the Central excise tariff enacted therein. It reads
as under:
1. Central Excise duty is now levied at the
rates specified in the First Schedule to the
Central Excises and Salt Act, 1944. The
Central Excises and Salt Act, 1944
originally provided for only 11 items. The
number of Items has since increased to
137. The levy, which was selective in
nature, to start with, acquired a
comprehensive coverage in 1975, when the
residuary Item 68 was introduced. Thus,
barring a few Items like opium, alcohol, etc.,
all other manufactured goods now come
under the scope of this levy.
2. The Technical Study Group on Central
Excise Tariff, which was set up by the
Government in 1984 to conduct a
comprehensive inquiry into the structure
of the Central excise tariff has
suggested the adoption of a detailed
Central excise tariff based broadly on
the system of classification derived from
the International Convention on the
Harmonised Commodity Description and
Coding System (Harmonised system)
with such contractions or modifications
thereto as are necessary to fall within the
scope of the levy of Central excise duty.
The Group has also suggested that the new
tariff should be provided for by a separate
Act to be called the Central Excise Tariff
Act.
JUDGMENT
3. The tariff suggested by the Study Group
Civil Appeal Nos. 4480 of 2005 & Anr. Page 8 of 28
Page 8
is based on an internationally accepted
nomenclature, in the formulation of which
all considerations, technical and legal, have
been taken into account. It should,
therefore, reduce disputes on account of
tariff classification. Besides, since the tariff
would be on the lines of the Harmonised
System , it would bring about considerable
alignment between the customs and Central
excise tariffs and thus facilitate charging of
additional customs duty on imports
equivalent to excise duty. Accordingly, it is
proposed to specify the Central excise tariff
suggested by the Study Group by a
separate tariff Act instead of the present
system of the tariff being governed by the
First Schedule to the Central Excises and
Salt Act, 1944.
4. The main features of the Bill are as
follows:
(i) The tariff included in the Schedule to the
Bill has been made more detailed and
comprehensive, thus obviating the need for
having a residuary tariff Item. Goods of the
same class have been grouped together to
enable parity in treatment .
xx xx xx
JUDGMENT
5. The Bill seeks to achieve the above
objects.(emphasis supplied)
12. It is significant, as expressly stated, in
the Statement of Objects and Reasons, that
the Central excise tariffs are based on the
HSN and the internationally accepted
nomenclature was taken into account to
"reduce disputes on account of tariff
classification". Accordingly, for resolving
any dispute relating to tariff classification, a
safe guide is the internationally accepted
nomenclature emerging from the HSN. This
being the expressly acknowledged basis of
the structure of Central excise tariff in the
Civil Appeal Nos. 4480 of 2005 & Anr. Page 9 of 28
Page 9
Act and the tariff classification made
therein, in case of any doubt the HSN is a
safe guide for ascertaining the true
meaning of any expression used in the Act.
The ISI Glossary of Terms has a different
purpose and, therefore, the specific
purpose of tariff classification for which the
internationally accepted nomenclature in
HSN has been adopted, for enacting the
Central Excise Tariff Act, 1985, must be
preferred, in case of any difference between
the meaning of the expression given in the
HSN and the meaning of that term given in
the Glossary of Terms of the ISI.”
8) He also pointed out that the aforesaid principle contained in
Wood Crafts Products was reiterated in CCE, Hyderabad v.
2
Bakelite Hylam as follows:
“17. Hence for the interpretation of the New
Tariff harmonised system of nomenclature
and its explanatory notes are relevant. In
the case of Collector of Central Excise,
Shillong v. Wood Crafts Products Ltd. 1995
(3) SCC 454, this Court, while considering
the Central Excise Tariff Act of 1985, has
held that looking to the Statement of
Objects and Reasons the Central Excise
Tariff under the 1985 Act is based on the
Harmonised System of Nomenclature (HSN)
and the internationally accepted
nomenclature has been adopted to reduce
disputes on account of tariff classification.
Accordingly, for resolving any dispute
relating to tariff classification, the
internationally accepted nomenclature
emerging from the HSN is a safe guide, this
being the expressly acknowledged basis of
the structure of the Central Excise Tariff in
the 1985 Act and the tariff classification
made therein. In case of any doubt, the
HSN is a safe guide for ascertaining the true
meaning of any expression used in the Act. ”
JUDGMENT
2 1997 (91) ELT 13
Civil Appeal Nos. 4480 of 2005 & Anr. Page 10 of 28
Page 10
9) Mr. Panda also referred to certain decisions of the Tribunals
wherein such shampoos with 2% anti-fungal agents were still
treated as shampoos and not a medicinal product. Notably,
among these decisions are (i) Amit Ayurvedic & Cosmetic
3
Products v. Commissioner and (ii) CCE Vapi v. Beta
4
Cosmetics .
10) Mr. Bagaria, learned senior counsel, appearing for the
respondent/assessee stoutly refuted the aforesaid arguments of
the Revenue laying great emphasis on the plea that the product in
question was basically a medicine which was pre-dominant use.
In order to demonstrate that the product 'Nizral Shampoo' could
only be used as medicine and not like any other general/ordinary
shampoo, he pointed out the following features which stood
JUDGMENT
established on record in the form of plethora of
materials/evidence placed before the authorities below:
(i) The medicinal properties of the product were adequately
emphasized and the product was sold by the assessee on that
basis in the market.
(ii) There was a warning to the patients about the adverse
reaction of the use of this shampoo, if used for a long period.
3 2004 (168) ELT 354
4 2004 (173) ELT 255
Civil Appeal Nos. 4480 of 2005 & Anr. Page 11 of 28
Page 11
(iii) The product was essentially described as 'medicine' only and
not as a shampoo meant for cleaning the hair.
(iv) The literature along with the product sold specifically stated
the diseases which could be cured by the use of this shampoo.
(v) Limited period use of the product was suggested, unlike a
normal shampoo which could be used regularly for infinite period.
11) Mr. Bagaria argued that matter needed to be examined keeping in
view the aforesaid essential attributes/characteristics of the
product and in this context, the fact that the product was held out
by the respondent to the public at large as medicine; availability of
the said product with the Chemists; sale of the product on the
prescription of a Doctor; assume much relevancy in treating the
product as medicament having therapeutic value and not as
ordinary shampoo.
JUDGMENT
12) Mr. Bagaria also pointed out that presence of 2% 'Ketoconazole'
in the said shampoo could not be treated as something
insignificant. On the contrary, it was the maximum percentage
required to treate the dandruff inasmuch as presence of more
'Ketoconazole' could be harmful. He further submitted that if it is
less than that, then it may lose its therapeutic value and for this
reason, in those shampoos where the assessee was earlier
Civil Appeal Nos. 4480 of 2005 & Anr. Page 12 of 28
Page 12
putting 1% to 1½% of 'Ketoconazole', the assessee was itself
treating the said product as shampoo only and not as
Pharmaceutical product. He concluded his arguments by
submitting that the judgment of this Court in B.P.L.
5
Pharmaceuticals Ltd. v. CCE, Vadodra squarely covered the
issue involved in this case.
13) We have considered the submissions of counsel for the parties
and find ourselves in agreement with the view taken by the
Tribunal holding that the product in question 'Nizral Shampoo' is
classifiable under CSH 3003.10 and not CSH 3305.99.
14) At the outset, we may mention that the product known as 'Nizral
Shampoo' gives the nomenclature of the product as shampoo.
However, the respondent claim that it is a patent or proprietary
JUDGMENT
medicament as it's essential characteristics is therapeutic in
nature. It is the common case of the counsel for the parties the
pre-dominant use of the product in question is to be taken into
consideration while deciding the classification issue. Therefore, it
is to be determined as to whether the product in question is
primarily used as a shampoo or it is used as a medicament. To
find answer to this question, it is necessary to keep in mind the
5 1995 Supp. (3) SCC 1
Civil Appeal Nos. 4480 of 2005 & Anr. Page 13 of 28
Page 13
essential characteristics of the product. When the matter is
examined from the aforesaid perspective we come to the
conclusion that the respondent is correct in submitting that the
essential properties of the product are medicinal in nature. It is
| imidazole dio | |
| clear from the following description:<br>“Pharmacodynamics<br>Ketoconazole, a synthetic<br>derivative ha a potent anti-fu<br>dermatophytes, such as<br>Epidermophyton sp. Micr<br>yeasts, such as candida<br>furfur (Pityrosporum oval<br>shampoo rapidly relieves s<br>which are usually associ<br>versicolor seborrhoeic derm<br>capitis (dandruff).<br>Pharmacokinetics<br>Percutaneous absorption<br>shampoo is negligible since<br>be detected, even after chro<br>effects, therefore, are not ex |
Indications
Treatment and prophylaxis of infections in which
the yeast pityrosporum is involved, such as
Pityriasis versicolor (localized), seborrhoeic
dermatitis and pityriasis capitis (dandruff).
JUDGMENT
Contra-indications
Known hypersensitivity to Ketoconazole or the
excipient.”
The manufacturer has given clear warning and precautions
for the use of this product which are follows:
“Warnings and Precautions
To prevent a rebound effect after stopping a
Civil Appeal Nos. 4480 of 2005 & Anr. Page 14 of 28
Page 14
prolonged treatment with topical corticosteroid it
is recommended to continue applying the topical
corticosteroid together with Nizral Shampoo 2%
and to subsequently and gradually withdraw the
steroid therapy over a period of 2-3 weeks.
| ”<br>ow the treat | |
| use of Nizral Shampoo 2%.”<br>It is further mentioned as to h<br>given to a person suffering from vario<br>“Treatment:<br>-Pityriasis versicolor; once d<br>days.<br>-Seborrhoeic dermatitis an<br>twice weekly for 2 to 4 weeks<br>Prophylaxis:<br>-Pityriasis versicolor: once d<br>days during a single treatme<br>summer.<br>-Seborrhoeic dermatitis an<br>once every one or two weeks | ” |
Even the adverse reaction of the treatment are mentioned
JUDGMENT
by the manufacturers with specific advice that overdoses of this
shampoo is not expected, as is clear from the following:
“Adverse reactions
Topical treatment with Nizral Shampoo 2% is
generally well tolerated. As with other
Shampoos, a local burning sensation, itching,
irritation and oily/dry hair may occur, but are rare,
during the period of use of Nizral Shampoo 2%.
In rare instances, mainly in patients with
chemically damaged hair or grey hair, a
discolouration of the hair has been observed.
Civil Appeal Nos. 4480 of 2005 & Anr. Page 15 of 28
Page 15
Overdosage
Not expected as Nizral Shampoo 2% is intended
for external use only. In the event of accident
ingestion, only supportive measures should be
carried out. In order to avoid aspiration, neither
emesis nor gastric lavage should be performed.”
| is stated, an<br>supplied by th | |
|---|---|
| 15) Thus, not only limited period use i<br>feature that appears in the literature s<br>the information for the 'patient', descr<br>as a 'patient'. It is as under:<br>“Patient information<br>Ketoconazole Shampoo 2<br>Nizral Shampoo 2%<br>You have been advised by<br>this shampoo to treat dandr<br>you some information that<br>mine while using Nizral Sha<br>some background informatio<br>is important for you to deal | i<br>s |
JUDGMENT
16) The use is suggested only on the advice of a Doctor and there is
a suggestion that Doctor should be consulted for any further
information. The respondent has also provided the
literature/material showing that dandruff is a disorder which
affects the hairy scalp. It is generally triggered by a single celled
organism which is kind of fungus, with scientific name
Civil Appeal Nos. 4480 of 2005 & Anr. Page 16 of 28
Page 16
'Pityrosporum Ovale'. For treatment of this disease, Nizral
Shampoo 2% (i.e. shampoo containing 2% 'Ketoconazole') is
shown as 'a new medicine' use whereof cures clears a dandruff.
It is suggested that it should be used once a week and on other
days, normal shampoos may be used which clearly shows that
'Nizral Shampoo' is to be used like a medicine, unlike other
normal Shampoos.
17) We also find that in order to show that the product was used only
as a medicament for curing dandruff and not for using the same
for the purpose of cleaning hair, the assessee filed affidavits of
various Doctors.
18) Having regard to the aforesaid material on record, we find that the
JUDGMENT
case is directly covered by the ratio of this Court's judgment in
B.P.L. Pharmaceuticals Ltd. (supra). That was a case where
the assessee was engaged in manufacture of Selenium Sulfide
Lotion which contained 2.5% selenium sulfide W/V. The
assessee was manufacturing this product under a loan licence
from Abbott Laboratories in accordance with Abbott's
specifications, raw materials, packing materials and quality
control. It was sold under the private name 'Selsun'. The
Civil Appeal Nos. 4480 of 2005 & Anr. Page 17 of 28
Page 17
assessee in that case claimed that this product was used in the
therapeutic quantity i.e. 2.5% W/V which was the only active
ingredient and other ingredient merely served the purpose of a
bare medium. It was also claimed that the product is
manufactured under a drug licence issued by the Food and Drug
Administration. The assessee, thus, wanted the product to be
classified under heading 3003.19 as Pharmaceutical Product
under Chapter 30. However, the Revenue took the plea that it
would fall under sub-heading 3305.90 i.e. under Chapter 33.
Thus, the respective contentions of the Department as well as the
assessee were almost on the same lines as in the present case,
namely, whether the said product was Pharmaceutical product or
it was a cosmetic/toiletry preparation. The only difference was of
sub-headings under those Chapters. This Court went into the
JUDGMENT
essential characteristics of the product and found it that dominant
use of the product was medicinal, as it was sold only on medical
prescription as a medicine for treatment of disease known as
Seborrhoeic Dermatitis, commonly known as Dandruff. It was
manufactured under a Drug Licence; the Food and Drug
Administration had certified it as a Drug; and the Drug Controller
had categorically opined that Selenium Sulfide present in Selsun
was in a therapeutic concentration etc. The relevant passages
Civil Appeal Nos. 4480 of 2005 & Anr. Page 18 of 28
Page 18
from the said judgment throwing light on these aspects are
reproduced below:
“19. So far as medicinal properties of the product
are concerned it can be gathered from the
technical and/or pharmaceutical references that
Selenium Sulfide has anti-fungal and
anti-seborrhoeic properties and is used in a
detergent medium for the treatment of dandruff
on the scalp which is milder form of Seborrhoeic
Dermatitis and Tinea Versicolour 2.5% of this
compound is the therapeutic quantity.
xx xx xx
24. Elaborating the above submissions, the
learned counsel for the respondents invited our
attention to chapter notes of Chapter 30 and
Chapter 33 and also the rules of interpretation.
According to the learned counsel a careful
reading of chapter notes of Chapter 30 would
show that preparations of Chapter 33 even if
they have therapeutic or prophylactic properties
would not fall under Chapter 30. However, he
fairly admitted that ‘medicaments’ are those that
have therapeutic or prophylactic uses.
Nevertheless those medicaments, if they are
classifiable under Chapter 33 or Chapter 34 will
not fall under Chapter 30, according to him, if
they are more specifically preparations falling
under Chapter 33 or Chapter 34. In other words,
he wants to equate the product in question to
‘shampoo’ enumerated under Heading No.
33.05. He also invited our attention to the fact
that the appellants before the coming into force
of the new Tariff Act described the product as
shampoo and they have omitted the word
‘shampoo’ deliberately only to claim that the
product would fall under Chapter 30.
JUDGMENT
25. We do not think that we can accept all the
contentions of the learned counsel for the
respondents except certain obvious admitted
positions. The submission that the product in
question must be equated to shampoo falling
under Chapter 33 is not at all correct.
Civil Appeal Nos. 4480 of 2005 & Anr. Page 19 of 28
Page 19
26. It is true that the learned counsel for the
appellants have placed reliance on the definition
of the words “cosmetic and drug” as defined in
the Drugs and Cosmetics Act, 1940. On a
perusal of the definitions, we can broadly
distinguish cosmetic and drug as follows:
“A ‘cosmetic’ means any article intended to be
rubbed, poured, sprinkled or sprayed on, or
introduced into, or otherwise applied to, the
human body or any part thereof for cleansing,
beautifying, promoting attractiveness, or
altering the appearance , and includes any
article intended for use as a component of
cosmetic.”
and
“A ‘drug’ includes all medicines for internal or
external use of human beings or animals and all
substances intended to be used for or in the
diagnosis, treatment, mitigation or prevention of
any disease or disorder in human beings or
animals , including preparations applied on
human body for the purpose of repelling
insects.”
27. We cannot ignore the above broad
classification while considering the character of
the product in question. Certainly, the product in
question is not intended for cleansing,
beautifying, promoting attractiveness or altering
appearance. On the other hand it is intended to
cure certain diseases as mentioned supra.
JUDGMENT
28. The fact that the appellants have previously
described the product as “Selsun Shampoo”
will not conclude the controversy when the true
nature of the product falls for determination. In
fact, notwithstanding the fact that the
appellants have described the product as
Selsun Shampoo, the Central Board of Excise
and Customs, as noticed earlier, has classified
the same as patent and proprietary medicine.
The respondents have accepted the same.
Therefore, there is no force in the submission
of the learned counsel for the respondents that
the product must be equated with shampoo.
29. The contention based on chapter notes is
also not correct. One of the reasons given by
the authorities below for holding that Selsun
Civil Appeal Nos. 4480 of 2005 & Anr. Page 20 of 28
Page 20
would fall under Chapter 33 was that having
regard to the composition, the product will
come within the purview of Note 2 to Chapter
33 of the Schedule to Central Excise Tariff Act,
1985 is without substance. According to the
authorities the product contains only subsidiary
pharmaceutical value and, therefore,
notwithstanding the product having a medicinal
value will fall under Chapter 33. We have
already set out Note 2 to Chapter 33. In order
to attract Note 2 to Chapter 33 the product
must first be a cosmetic, that the product
should be suitable for use as goods under
Headings Nos. 33.03 to 33.08 and they must
be put in packing as labels, literature and other
indications showing that they are for use as
cosmetic or toilet preparation. Contrary to the
above in the present case none of the
requirements are fulfilled. Therefore, Note 2 to
Chapter 33 is not attracted. Again it is without
substance the reason given by the authorities
that the product contains 2.5% w/v of Selenium
Sulfide which is only of a subsidiary curative or
prophylactic value. The position is that
therapeutic quantity permitted as per technical
references including US Pharmacopoeia is
2.5%. Anything in excess is likely to harm or
result in adverse effect. Once the therapeutic
quantity of the ingredient used, is accepted,
thereafter it is not possible to hold that the
constituent is subsidiary. The important factor is
that this constituent (Selenium Sulfide) is the
main ingredient and is the only active
ingredient.
JUDGMENT
xx xx xx
33. The labels which give the warning,
precaution and directions for use do make a
difference from that of ordinary shampoo which
will not contain such warning or precautions for
use. Further no individual would be prepared to
say in a social gathering that he or she is using
Selsun to get rid of dandruff or other similar
diseases whereas nobody would hesitate to
state in a similar gathering that he or she is
Civil Appeal Nos. 4480 of 2005 & Anr. Page 21 of 28
Page 21
using a particular brand of shampoo for
beautifying his or her
hair. Thus there are lot of
favourable materials to treat the product in
question as a medicine rather than cosmetic. In
this connection the reliance placed by the
learned counsel for the appellants on a
decision of this Court reported in case Indian
Metals & Ferro Alloys Ltd. v. CCE can be
usefully referred to. In that case this Court held:
“It (the Tribunal) seems to say that, even if the
goods manufactured by the appellant had been
rightly classified under Item 26-AA before
1-3-1975, the introduction of Item 68 makes a
difference to the interpretation of Item 26-AA.
This is not correct. Item 68 was only intended
as a residuary item. It covers goods not
expressly mentioned in any of the earlier items.
If, as assumed by the Tribunal, the poles
manufactured were rightly classified under Item
26-AA, the question of revising the
classification cannot arise merely because Item
68 is introduced to bring into the tax net items
not covered by the various items set out in the
Schedule. It does not and cannot affect the
interpretation of the items enumerated in the
Schedule. This logic of the Tribunal is,
therefore, clearly wrong.”
34. This judgment supports the case of the
appellant when it is contended that there is no
good reason to change the classification merely
on the ground of coming into force of the new
Central Excise Tariff Act, 1985 without showing
more that the product has changed its
character.
JUDGMENT
35. The learned counsel also placed reliance
on a number of judgments to support his
argument that in common and commercial
parlance the product is known as medicine
rather than cosmetic. As pointed out already
and in support of that submission, affidavits
and letters from chemists, doctors and
customers are filed to show that the product is
sold under prescription only in chemists’ shops
unlike shampoos sold in any shop including
provision shops. This conclusion, namely, that
the product is understood in the common and
Civil Appeal Nos. 4480 of 2005 & Anr. Page 22 of 28
Page 22
commercial parlance as a patent and
proprietary medicine was also found by the
Central Board of Excise and Customs as early
as in 1981 and accepted by the Excise
authorities and in the absence of any new
material on the side of the respondents there is
no difficulty in accepting this contention without
referring to decision cited by the counsel for the
appellants.
36. Yet another reason given by the CEGAT for
not accepting the case of the appellants was
that the product is sold with a pleasant odour
and, therefore, it must be treated as a
cosmetic. Selenium Sulfide has an unpleasant
odour and to get rid of it insignificant amount of
perfume is used and make it acceptable to the
consumers. A medicine, for example,
sugar-coated pill will nevertheless be medicine
notwithstanding the sugar-coating. Likewise the
addition of insignificant quantity of perfume to
suppress the smell will not take away the
character of the product as a drug or medicine.
Again one other reason given by the Tribunal is
regarding the packing. The Tribunal has held
that the product is cosmetic because it is
packed in an attractive plastic bottle. This by
itself will not change the character, as cosmetic
is put up for sale with some indication on the
bottle or label that it is to be used as cosmetic
or it is held out to be used as a cosmetic. As
already noted the label here gives warnings.
The fact that it is packed in a plastic bottle is a
wholly irrelevant criteria.”
JUDGMENT
19) The aforesaid judgment not only provides a complete answer to
the issue at hand, it also suitably answers the various arguments
of the Revenue and the manner in which those arguments were
rebutted by the Court in the said case. The Tribunal has summed
up the entire legal proposition in para 5 of its judgment with which
we entirely agree. This para reads as under:
Civil Appeal Nos. 4480 of 2005 & Anr. Page 23 of 28
Page 23
“5. We have carefully considered the
submissions made by the learned Counsel and
the learned DR. We find from the extracted
literature that the item comprises of 20 mg
Ketoconazole in one ml and the pamphlet
clearly indicates that it is for the use only of a
Registered Medical Practitioner or a Hospital or
a Laboratory. The pamphlet claims that the item
is used for treatment and prophlaxis of
infections in which the yeast pityrosporum is
involved such as pityriasis versicolor (localized),
seborrhoeic dermatitis and pityriasis
capitis(dandruff). The procedure for treatment
and the adverse reactions on such treatment
due to overdose is also stated in the pamphlet.
The Apex court, in the case of Muller & Phipps
(India) Ltd. v. CCE, 2004 (167) ELT 347 (SC)
has clearly held that once the item has been
manufactured under a Drug licence and the
Department has treated the item as a Drug, it
would not cease to be one notwithstanding the
fact that new Tariff Act has come into force. The
Apex Court again held in the case of CCE v.
Pandit D.P. Sharma, 2003 (154) ELT 324 (SC)
that once in the common parlance the item is
treated as a medicament and manufactured
under drug licence and the evidence is
produced by the party with regard to the item
being a medicament, then it should be treated
as such and should not treat 'Himtaj Oil' as
'perfumed hair oil'. The Apex Court's ruling in the
case of B.P.L. Pharmaceuticals Ltd. v. CCE,
1995 (77) ELT 485 has held that 'Selsun' and
anti-dandruff preparation containing 2.5%
selenium sulphide which is full therapeutic limit
permissible as per pharmacopoeia and
manufactured under Drug Licence and certified
by Food and Drugs Administration as a
medicine, and the same is put up as a medicine
to be used under Doctor's advise in
accompanying literature and sold through
chemist shops under doctor's prescription
should be considered as a medicament under
Sub-Heading 3003.19 of CE Act and not as a
cosmetics. In the present case also, same
evidence is relied which are identical to the facts
of B.P.L. Pharmaceuticals Ltd. The item also
JUDGMENT
Civil Appeal Nos. 4480 of 2005 & Anr. Page 24 of 28
Page 24
acts as an anti-dandruff preparation with 2%
Ketoconazole. The same is sold on doctor's
prescription and by the chemists and
understood as a medicine in common parlance
as per the enormous literature and affidavit
produced. Therefore, there was no necessity for
the Commissioner to have distinguished this
Apex Court judgment which applies on all fours
to the facts of the present case. We also find
that the judgment of the Apex Court rendered in
the case of CCE v. Vicco Laboratories, 2005
(179) ELT 17 (SC) also applies to the facts of
the case. In this case, the Apex Court has
clearly noted that the common parlance test
should be applied for determining whether a
product is classificable as a pharmaceutical
product under Chapter 30 of CET Act or as a
cosmetics under Chapter 33 ibid as laid down
by the Supreme Court in the case of Shree
Baidyanath Ayurved Bhavan Ltd., 1996 (83) ELT
492 (SC). As there is enormous evidence
produced by the appellants with regard to the
use of Ketoconazole Shampoo for treatment of
several disorders and diseases mentioned in the
pamphlet and the same is sold by a chemist
under a prescription issued by a Registered
medical Practitioner or a Hospital or a
Laboratory, therefore, the appeal is required to
be allowed with consequential relief, if any.”
JUDGMENT
20) We, thus, are of the view that the judgment of the Tribunal does
not call for any interference and the appeal is dismissed with cost.
CIVIL APPEAL NO. 5752 OF 2015
(arising out of SLP (C) No. 1531 of 2015)
21) Leave granted.
22) This appeal is preferred by the assessee and the issue arises is
the same as discussed in Civil Appeal No. 4480 of 2005. Here,
respondent No.2 has passed an order directing the appellant to pay
Civil Appeal Nos. 4480 of 2005 & Anr. Page 25 of 28
Page 25
differential duty, treating the product as Shampoo and not
Medicaments. Challenging that order, appellant had filed the writ
petition, which has been dismissed by the High Court vide impugned
judgment primarily on the ground the matter had left to the concerned
authority to decide the classification on the basis of technical evaluation
and it could not be decided by the High Court. For the reasons
recorded in Civil Appeal No. 4480 of 2005, this appeal stands allowed
hereby quashing the order of the High Court as well as respondent
No.2 dated 28.12.2001 demanding differential duty.
.............................................J.
(A.K. SIKRI)
.............................................J.
(ROHINTON FALI NARIMAN)
JUDGMENT
NEW DELHI;
MAY 14, 2015.
Civil Appeal Nos. 4480 of 2005 & Anr. Page 26 of 28
Page 26
ITEM NO.101 COURT NO.12 SECTION III
S U P R E M E C O U R T O F I N D I A
RECORD OF PROCEEDINGS
Civil Appeal No(s). 4480/2005
COMMISSIONER OF CENTRAL EXCISE HYDERABAD Appellant(s)
VERSUS
M/S SARVOTHAM CARE LIMITED Respondent(s)
WITH
SLP(C) No. 1531/2015
(With Interim Relief and Office Report)
Date : 14/05/2015 These matters were called on for hearing
today.
CORAM :
HON'BLE MR. JUSTICE A.K. SIKRI
HON'BLE MR. JUSTICE ROHINTON FALI NARIMAN
For Appellant(s) Mr. A.K.Panda,Sr.Adv.
Mr. Rajiv Nanda,Adv.
Mr. T.M.Singh,Adv.
Mr. B. Krishna Prasad,Adv.
Mr. S.K.Bagaria,Sr.Adv.
Mr. Alok Yadav,Adv.
Mr. Anuj B.,Adv.
Mr. Udit Jain,Adv.
Mr. Ajit,Adv.
Mr. Harish Pandey,Adv.
JUDGMENT
For Respondent(s) Mr. S.K.Bagaria,Sr.Adv.
Mr. Alok Yadav,Adv.
Mr. Anuj B.,Adv.
Mr. Udit Jain,Adv.
Mr. Ajit,Adv.
Mr. Rajan Narain,Adv.
UPON hearing the counsel the Court made the following
O R D E R
The Civil Appeal No. 4480 of 2005 is dismissed with cost.
Civil Appeal Nos. 4480 of 2005 & Anr. Page 27 of 28
Page 27
Leave granted.
The Civil Appeal No. 5752 of 2015 arising
out of SLP(C)NO. 1531 of 2015 stands allowed hereby
quashing the order of the High Court as well as
respondent No.2 dated 28.12.2001 demanding
differential duty.
(SUMAN WADHWA)
AR-cum-PS
(SUMAN JAIN)
COURT MASTER
Signed Reportable judgment is placed on the file.
JUDGMENT
Civil Appeal Nos. 4480 of 2005 & Anr. Page 28 of 28
Page 28